Daunoxome en es it fr

Daunoxome Brand names, Daunoxome Analogs

Daunoxome Brand Names Mixture

  • No information avaliable

Daunoxome Chemical_Formula


Daunoxome RX_link


Daunoxome fda sheet


Daunoxome msds (material safety sheet)

Daunoxome MSDS

Daunoxome Synthesis Reference

J. P. Parsh et al. J. Pharm. Sci. 56, 1691 (1967);

Daunoxome Molecular Weight

527.52 g/mol

Daunoxome Melting Point

208-209 oC

Daunoxome H2O Solubility

39.2 mg/L

Daunoxome State


Daunoxome LogP


Daunoxome Dosage Forms

Powder for solution; Suspension

Daunoxome Indication

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Daunoxome Pharmacology

Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Daunoxome Absorption

No information avaliable

Daunoxome side effects and Toxicity

LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)

Daunoxome Patient Information

Daunoxome Organisms Affected

Humans and other mammals